Brain scans may reveal how naltrexone works in teens with eating disorders

NCT ID NCT05509257

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether functional MRI (fMRI) brain scans can detect changes caused by a single dose of naltrexone in adolescents aged 13-21 with eating disorders involving binge eating or purging. Participants receive both naltrexone and a placebo in random order, two weeks apart, and undergo brain imaging. The goal is to see if the drug alters activity in reward-related brain regions, which could lead to a new way to measure drug effects in future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Naltrexone
What this could lead to
If successful, this could provide a reliable brain-based test to measure how well opioid-blocking drugs work in eating disorders, potentially guiding future treatments.
What could go wrong
This is a very early, small study (60 participants) focused on measuring brain activity, not treating the disorder. The drug is given only once, so it cannot show long-term effects or real-world benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANOREXIA NERVOSA, ATYPICAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Mercy Research Institute

    RECRUITING

    Kansas City, Missouri, 64108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.